Defining reliable disability outcomes in multiple sclerosis.
暂无分享,去创建一个
Pierre Grammond | Murat Terzi | Guillermo Izquierdo | Jeannette Lechner-Scott | Helmut Butzkueven | Maria Trojano | Freek Verheul | Dana Horakova | Alessandra Lugaresi | Tim Spelman | Orla Gray | Francois Grand'Maison | Michael Barnett | Raed Alroughani | Tomas Kalincik | Roberto Bergamaschi | Cavit Boz | Gerardo Iuliano | Daniele Spitaleri | J. Lechner-Scott | M. Slee | M. Trojano | G. Cutter | F. Grand'Maison | E. Havrdová | H. Butzkueven | R. Bergamaschi | M. Barnett | G. Izquierdo | A. Lugaresi | C. Boz | C. Oreja-Guevara | P. Duquette | E. Cristiano | R. Hupperts | A. Prat | M. Girard | T. Spelman | D. Horáková | T. Kalincik | P. Grammond | V. van Pesch | R. Fernández‐Bolaños | G. Iuliano | O. Gray | F. Verheul | M. Fiol | R. Alroughani | J. Cabrera-Gomez | V. Jokubaitis | E. Pucci | Marc Girard | Gary Cutter | C. Ramo | Celia Oreja-Guevara | Pierre Duquette | Alexandre Prat | Eva Havrdova | M. Terzi | D. Spitaleri | J. Sanchez-Menoyo | Raymond Hupperts | Marcela Fiol | Mark Slee | Vilija Jokubaitis | Eugenio Pucci | Vincent Van Pesch | Edgardo Cristiano | Ricardo Fernandez-Bolaños | Cristina Ramo | José Luis Sánchez-Menoyo | Jose Antonio Cabrera-Gomez | J. Sánchez-Menoyo
[1] C. Pozzilli,et al. Clinical markers of therapeutic response to disease modifying drugs , 2008, Neurological Sciences.
[2] L. Fratiglioni,et al. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. , 1988, Archives of neurology.
[3] References , 1971 .
[4] P. Adeleine,et al. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. , 2003, Brain : a journal of neurology.
[5] Thomas Kohlmann,et al. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis , 2013, BMC Neurology.
[6] B. Healy,et al. Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies , 2011, Journal of Neurology.
[7] D. Bourdette,et al. Inter‐ and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS) , 1992, Neurology.
[8] L. Blumhardt,et al. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts , 2000, Journal of neurology, neurosurgery, and psychiatry.
[9] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[10] E J Orav,et al. Disease steps in multiple sclerosis: a longitudinal study comparing Disease Steps and EDSS to evaluate disease progression , 1999, Multiple sclerosis.
[11] B. Uitdehaag. Clinical outcome measures in multiple sclerosis. , 2014, Handbook of clinical neurology.
[12] Yinshan Zhao,et al. Natural, innate improvements in multiple sclerosis disability , 2012, Multiple sclerosis.
[13] L. Kappos,et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis , 2006, Multiple sclerosis.
[14] F. Mcdowell,et al. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.
[15] Gilles Edan,et al. Evidence for a two-stage disability progression in multiple sclerosis , 2010, Brain : a journal of neurology.
[16] F. Lublin,et al. Effect of relapses on development of residual deficit in multiple sclerosis , 2003, Neurology.
[17] P. Sørensen,et al. Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale , 2005, Multiple sclerosis.
[18] C. Lederer,et al. Disability as an outcome in MS clinical trials , 2008, Neurology.
[19] J. Noseworthy,et al. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial , 1990, Neurology.
[20] F. Jacques. Defining the clinical course of multiple sclerosis: The 2013 revisions , 2015, Neurology.
[21] C. Di Pietrantonj,et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. , 2013, The Cochrane database of systematic reviews.
[22] J. Baskerville,et al. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS , 1996, Neurology.
[23] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[24] Anthony Traboulsee,et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.
[25] J. Lechner-Scott,et al. Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis , 2013, PloS one.
[26] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[27] J. Lechner-Scott,et al. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. , 2013, Brain : a journal of neurology.
[28] G. Ingram,et al. Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome , 2012, Multiple sclerosis.